The findings suggest clinicians don’t need to be as aggressive in lowering BP in this population, at least early after ...

Lifesaving therapy offers hope for patients with advanced heart failure, serving as a bridge to heart transplantation or long-term therapy. WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- MedStar Washington ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.

ST. PAUL, Minn.-- (BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the company has received an Innovation Award for its HeartMate 3 ™ Left ...

SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...

ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart pump ...

Abbott Laboratories' HeartMate 3 heart pump for advanced heart failure kept more patients alive for two years with fewer incidents of stroke than the company's prior left ventricular assist device ...

ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...

When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...

Abbott announced on October 19, 2018 that its HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living ...